All News

The venerable American Association for Advertising is welcoming the return of its prodigal son-the healthcare agency and its clients-by including a Health & Wellness category in its 2016 Partner Award. Marylyn Donahue reports.

The industry’s much talked-about patient-centered approach requires more than lip-service and organizational redesigns. For the patient to emerge center stage in a commercial approach after having languished in the wings for years necessitates a totemic shift on the part of manufacturers that aligns both R&D and marketing in focusing squarely on patient needs to drive positive outcomes- clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market. This eBook offers actionable strategies, targeted solutions, and specific directions on how to get there.

 .

Prix Galien USA had its day, a fall tradition bringing the celebs of the biopharma industry to New York City for discussion and debate and a night of glitz. Casey McDonald reports.

Doctors, advocates, politicians, feds jump on price-gouging bandwagon

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share.

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage.

October 26, 2015.

Hillary Clinton has been a part of the healthcare debate since the early 90's. Tom Norton analyzes her career of positions on drug price control and what it could mean for her candidacy.

Success in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.

UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, is has questioned pharma’s connections to the influential and highly visible American Heart Association (AHA). Casey McDonald reports.

The issue of drug price controls in public prescription programs has long been a point of contention. But today, writes Tom Norton, as several historical and contemporary factors continue to line up, we may be on a pathway to changing that.

A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.

August 11, 2015.

An internal audit of payment practices in Eastern Europe has revealed payments for elaborate travel for government health authorities and state-employed physicians in exchange for approval and prescription of your products. What is the first thing you should do? Lawyer Mara Senn offers some advice.

Amgen and Sandoz received a decision from the U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday. PharmExec spoke with legal and biosimilar experts for their initial reactions.

July 9, 2015.